Mark Lepore

Mark Lepore, M.D.

Chief Medical Officer, Allergy

Dr. Lepore joined Aquestive in December of 2020.  Prior to joining Aquestive, Dr. Lepore was the Vice President of Global Clinical Strategy and Development for Lupin.  In that role he led all clinical activities for inhalation drug-device and complex injectable products, with a focus on the U.S. and Europe.  From 2008 to 2013, Dr. Lepore held various roles at Teva, where he helped develop several 505(b)(2) inhaled drug-device products, including Proair Respiclick, Airduo Respiclick, and for Europe, Duoresp Spiromax.    Prior to 2008, Dr. Lepore was a partner, practicing physician, and clinical researcher with Allergy and Asthma Specialists in Blue Bell, Pennsylvania.  During his time in practice, Dr. Lepore contributed to over 100 industry-sponsored clinical trials.  Dr. Lepore received his BS degree in Biology from St. Joseph’s University in Philadelphia, and his MD from Jefferson Medical College of Thomas Jefferson University in Philadelphia. He completed his residency in Pediatrics at University of Maryland Medical System, and his fellowship in Allergy/Clinical Immunology at Cincinnati Children’s Hospital Medical Center.  Dr. Lepore has board certified both in General Pediatrics and Allergy/Clinical Immunology, and is a Fellow of the American Academy of Allergy, Asthma, and Immunology.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”